文献速递肿瘤 PET/CT神经核医学

68Ga-NOTA-Exendin-4 PET/CT与68Ga-DOTATATE、18F-FDG及常规影像在胰岛素瘤定位中的比较

Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-22

该前瞻性研究纳入47例生化证实的內源性高胰岛素性低血糖患者,比较68Ga-NOTA-Exendin-4(Ex4)PET/CT与其他影像方法定位胰岛素瘤的效能。患者层面Ex4 PET/CT的灵敏度和准确率分别为94.11%和95.74%,高于68Ga-DOTATATE PET/CT、18F-FDG PET/CT、CE-CT和CE-MRI。结论认为Ex4 PET/CT在良性胰岛素瘤定位方面优于常规影像方法。

要点

  • 患者层面Ex4 PET/CT灵敏度94.11%、准确率95.74%,高于68Ga-DOTATATE PET/CT的70.59%和78.72%。
  • Ex4 PET/CT观察者间一致性Cohen κ为0.839,高于68Ga-DOTATATE PET/CT的0.707和18F-FDG PET/CT的0.784。
  • Ex4与68Ga-DOTATATE PET/CT的SUVmax和TBR均显著高于18F-FDG PET/CT(p < 0.01)。

核心结论

  • Ex4 PET/CT在良性胰岛素瘤定位方面显示出优于常规影像方法的特性。
  • Ex4 PET/CT的成像质量和可解释性优于18F-FDG PET/CT和68Ga-DOTATATE PET/CT。
  • 联合Ex4与68Ga-DOTATATE PET/CT可对胰岛素瘤提供全面的评估与定位。

研究设计与样本

  • 前瞻性研究,纳入47例生化证实的內源性高胰岛素性低血糖患者。
  • 患者均接受Ex4 PET/CT及其他影像方法检查,由经验丰富(>10年)和初级(<2年)核医学医师分别判读。
  • 在患者层面和病灶层面计算各影像方法定位胰岛素瘤的灵敏度和准确率。
  • 试验于2024年11月14日和2024年12月5日在ClinicalTrials.gov回顾性注册(NCT06690957和NCT06725693)。

主要发现

  • 患者层面Ex4 PET/CT灵敏度94.11%、准确率95.74%,高于68Ga-DOTATATE PET/CT(70.59%,p = 0.026;78.72%,p = 0.030)。
  • 患者层面Ex4 PET/CT灵敏度94.11%、准确率95.74%,高于18F-FDG PET/CT(50.00%,p < 0.001;63.83%,p < 0.001)。
  • 患者层面Ex4 PET/CT准确率95.74%高于CE-CT的72.22%(p = 0.007),灵敏度94.11% vs CE-CT的77.77%(p = 0.135)。
  • 患者层面Ex4 PET/CT准确率95.74%高于CE-MRI的43.75%(p < 0.001),灵敏度94.11% vs CE-MRI的63.64%(p = 0.135)。
  • Ex4 PET/CT观察者间一致性Cohen κ为0.839,高于68Ga-DOTATATE PET/CT的0.707和18F-FDG PET/CT的0.784。

关键数值与推荐

  • Ex4与68Ga-DOTATATE PET/CT的SUVmax和TBR均显著高于18F-FDG PET/CT(p < 0.01)。
  • 肿瘤Ki-67与68Ga-DOTATATE PET/CT的SUVmax呈负相关(r = -0.637,p < 0.001)。
  • 三种分子影像方法的SUVmax和TBR与最大肿瘤直径呈正相关(p < 0.05),但18F-FDG PET/CT的TBR除外。
  • 三种示踪剂的半定量值与最低血糖水平、对应胰岛素和C肽水平均无相关性。
  • 68Ga-DOTATATE PET/CT的TBR与C肽呈正相关(r = 0.393,p = 0.043)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Accurate preoperative localization is particularly important for surgical treatment of insulinomas. Current imaging methods, including 18F-FDG (FDG) PET/CT, 68Ga-DOTATATE (TATE) PET/CT, CE-CT, and CE-MRI, have limitations. This prospective study provides a direct comparison of 68Ga-NOTA-Exendin-4 (Ex4) PET/CT with other imaging techniques. METHOD: 47 patients with biochemically proven endogenous hyperinsulinemic hypoglycemia underwent Ex4 PET/CT and other imaging methods. Sensitivity and accuracy of all imaging procedures for localizing insulinoma were calculated at the patient level and lesion level. Both clinical (>10 years experience) and junior (< 2 years experience) nuclear medicine physician readings were used to assess the diagnostic efficacy. We compared the SUVmax and tumor-to-background ratio (TBR) of three tracers and analyzed the values with Ki-67, maximum tumor diameter, and glucose metabolism indicators. RESULTS: In patient level, the sensitivity and accuracy of Ex4 PET/CT (94.11% and 95.74%) were higher than TATE PET/CT (70.59%, p = 0.026; 78.72%, p = 0.030), FDG PET/CT (50.00%, p < 0.001; 63.83%, p < 0.001), CE-CT (77.77%, p = 0.135; 72.22%, p = 0.007), and CE-MRI (63.64%, p = 0.135; 43.75%, p < 0.001), respectively. Interobserver agreement was higher for Ex4 PET/CT than TATE PET/CT and FDG PET/CT (Cohen κ, 0.839 vs. 0.707 and 0.784, respectively). SUVmax and TBR of Ex4 and TATE PET/CT were significantly higher than FDG PET/CT (p < 0.01). Negative correlations of tumor Ki-67 with TATE PET/CT were observed with SUVmax (r = -0.637, p < 0.001). SUVmax and TBR of three molecular imaging methods had positive correlations with the maximum tumor diameter (p < 0.05), except TBR of FDG PET/CT. Semi-quantitative values of the three tracers showed no correlation with the lowest blood glucose level, corresponding insulin, and C-peptide level. TBR of TATE PET/CT showed a positive correlation with C-peptide (r = 0.393, p = 0.043). CONCLUSION: Ex4 PET/CT showed superior characteristics in localization compared to routine imaging modalities in benign insulinomas. Ex4 PET/CT demonstrates better imaging quality and interpretability than FDG PET/CT and TATE PET/CT. Combined Ex4 and TATE PET/CT could provide a comprehensive evaluation/localization of insulinoma. TRIAL REGISTRATION: The trial was retrospectively registered at ClinitalTrial.gov (NCT06690957 and NCT06725693) on November 14, 2024 and December 5, 2024.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yu H, Bao X, Gu Y, et al. Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas. Eur J Nucl Med Mol Imaging. 2025. PMID: 40259061. doi:10.1007/s00259-025-07288-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。